Medical Cannabis for Cancer Patients
Cannabis can ease chemotherapy side effects; it does not cure cancer or replace standard treatment.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
Cannabis helps some cancer patients manage side effects—mainly nausea from chemo, and possibly pain and sleep. Two synthetic THC drugs (dronabinol, nabilone) are FDA-approved and have decades of use. Lab studies show cannabinoids kill cancer cells in dishes and mice; human trials have not shown cannabis shrinks tumors or extends survival. 'Rick Simpson Oil' and strain-based 'cures' are folklore. Cannabis works best alongside your oncology team, not instead of it.
Plain-language summary
Cannabis and cannabinoid medicines can help some cancer patients with certain side effects and symptoms. The most solid evidence is for preventing nausea and vomiting from chemotherapy, where two FDA-approved drugs—dronabinol (Marinol) and nabilone (Cesamet)—have been used for decades [1][2].
Cannabis may also help with pain, appetite loss, anxiety, and sleep in cancer patients, though the evidence is weaker and results are mixed [3][4][5].
What cannabis has not been shown to do is cure cancer, shrink tumors, or extend survival in humans [6]. Laboratory studies in cells and mice have shown that cannabinoids can kill some cancer cells, but this has not translated to real-world benefit for patients. Anyone marketing 'Rick Simpson Oil' or any cannabis product as a cancer cure is selling folklore, not medicine [7].
Important: This article is not medical advice. Cancer treatment decisions belong between you and your oncology team. Cannabis can interact with chemotherapy drugs, immunotherapy, and other medications, so your doctor must know if you are considering it [8].
What probably works: strong evidence
Chemotherapy-induced nausea and vomiting (CINV) Strong evidence
A Cochrane systematic review found that cannabis-based medicines reduced nausea and vomiting better than placebo and were roughly comparable to older antiemetic drugs [1]. Dronabinol and nabilone are FDA-approved specifically for CINV, typically offered as second-line agents when standard first-line drugs (5-HT3 antagonists like ondansetron, or NK1 antagonists like aprepitant) fail or cause intolerable side effects [2].
Modern antiemetic regimens have improved substantially over the past 20 years, so cannabis-based drugs are less commonly used as a first choice now than they were in the 1980s. They remain a legitimate option for breakthrough nausea in patients who do not respond to or cannot tolerate conventional agents.
What might work: weak or mixed evidence
Cancer pain Weak / limited
Nabiximols (Sativex, a THC:CBD oromucosal spray) has been studied for cancer pain that does not respond to opioids. Early phase II trials showed promise, but three large phase III randomized controlled trials failed to meet their primary endpoints for pain reduction compared to placebo [9]. Some subgroups in post-hoc analyses appeared to benefit more than others, but these findings are not reliable for predicting individual response.
Cannabis is not a reliable substitute for opioids in severe cancer pain. It may help some patients as an add-on treatment, but this remains unproven in controlled settings [9].
Cancer-related anxiety, insomnia, and low mood Weak / limited
Most evidence comes from observational surveys in which cancer patients self-report that cannabis helps their mood and sleep [3]. Controlled trials are few. Placebo effects in symptom management are substantial, and it is difficult to separate cannabis benefit from expectation, improved coping, or resolution of nausea (which itself disrupts sleep). Studies in non-cancer anxiety and insomnia suggest some benefit, but the translation to the cancer setting is unclear [10].
Cancer-related cachexia (wasting and appetite loss) Weak / limited
A randomized controlled trial comparing THC, a THC+CBD extract, and placebo in advanced cancer patients found no significant improvement in appetite, weight gain, or quality of life over placebo [11]. Corticosteroids and progestins like megestrol acetate have somewhat more evidence in this setting, though all available options remain imperfect [5].
What doesn't work: no good evidence
Cannabis as a cancer cure or tumor-shrinking agent No data
Preclinical (laboratory) studies have shown that THC and CBD can trigger cancer cell death in cells grown in dishes and in tumors implanted in mice [3][4]. This has created a large online ecosystem of testimonials, 'Rick Simpson Oil' protocols, and YouTube videos claiming that cannabis cures various cancers.
Human clinical trials do not support these claims. A small pilot study of THC injected directly into the brain in nine patients with recurrent glioblastoma in 2006 [12] and a phase 1b trial combining nabiximols with standard chemotherapy (temozolomide) in glioblastoma patients [13] found no evidence of tumor shrinkage or survival benefit that would justify using cannabis in place of standard oncologic treatment.
A large observational study of cancer patients found that those who chose alternative medicine—including cannabis—instead of conventional treatment had worse survival outcomes [6]. This is not proof that cannabis caused the worse outcome, but it reflects the reality that delaying or replacing proven cancer therapy with unproven alternatives carries serious risk.
Specific 'cure' ratios or strains No data
Claims like '1:1 CBD:THC cures breast cancer,' 'high-CBD oil dissolves tumors,' or strain names predicting anti-cancer effect are marketing folklore. The common claim that indica vs sativa matters for cancer treatment has no scientific basis.
What we don't know
- Whether cannabinoids have any meaningful anti-tumor effect in humans at doses that are safe and tolerable, and if so, in which cancers and at what doses.
- The optimal dose, THC:CBD ratio, and route of administration (smoking, vaping, oral, spray) for symptom relief in each clinical situation.
- Whether long-term cannabis use during cancer treatment affects recurrence risk or overall survival.
- Interaction with immunotherapy: One observational study found that cancer patients using cannabis during nivolumab (a checkpoint inhibitor immunotherapy) had lower response rates and worse outcomes [14]. This is an association, not proof of causation, but it is concerning enough that many oncologists now advise caution. This needs prospective study.
- Interactions with chemotherapy: CBD is a known inhibitor of the liver enzymes CYP3A4 and CYP2C9, which metabolize many chemotherapy drugs [8]. Whether this causes clinically significant interactions at typical cannabis doses is not well studied. Individual chemotherapy sensitivity, dose adjustments, and the potential for toxicity remain unclear.
Comparison with standard treatments
For chemotherapy-induced nausea:
Modern regimens (5-HT3 antagonists like ondansetron combined with NK1 antagonists like aprepitant and dexamethasone) are effective for most patients and are standard first-line treatment [2]. Dronabinol or nabilone are typically reserved for breakthrough nausea or when standard drugs fail or are not tolerated.
For cancer pain:
Opioids remain the standard treatment for moderate-to-severe cancer pain, supported by decades of trial data [2]. Cannabis is considered an adjunct, not a replacement. Some patients report reduced opioid use when adding cannabis, but randomized data specifically supporting an opioid-sparing effect in cancer patients is limited [9].
For appetite and cachexia:
Short-term corticosteroids and progestins like megestrol acetate have more evidence than cannabinoids, though all options are only modestly effective [5]. Treatment choice depends on the patient's goals and tolerance of side effects.
For anti-tumor treatment:
There is no comparison. Cannabis is not a cancer treatment. Standard-of-care therapy—surgery, chemotherapy, radiation, immunotherapy, targeted therapy—has years of clinical trial data supporting efficacy and safety in specific cancers. Replacing these with cannabis is associated with worse outcomes [6].
Risks and practical considerations
Drug interactions Weak / limited
CBD inhibits the liver enzymes CYP3A4 and CYP2C9, which metabolize many chemotherapy drugs, anticoagulants (warfarin), and other medications [8]. Dose adjustments or avoidance may be necessary. Inform your oncologist and pharmacist about any cannabis use.
Reduced immunotherapy efficacy Weak / limited
One observational study suggested that cannabis users had lower response rates to checkpoint inhibitor immunotherapy and worse survival [14]. Discuss cannabis use with your oncologist before starting immunotherapy.
Contamination Weak / limited
Illicit or unregulated cannabis may contain pesticides, heavy metals, or microbial contamination—especially concerning in immunocompromised cancer patients. Aspergillus contamination in cannabis products has caused fatal lung infections in immunocompromised patients. If considering cannabis, prioritize regulated, tested products from licensed sources where available.
Cognitive effects and falls
Cannabis can impair cognition and increase fall risk, particularly in older patients taking multiple sedating medications. This is especially concerning in advanced cancer patients with fatigue or bone metastases.
Cannabis hyperemesis syndrome
Heavy chronic cannabis use can paradoxically worsen nausea—a phenomenon called cannabis hyperemesis syndrome. This is easily mistaken for progressive chemotherapy side effects or disease.
Cost and legality
Cannabis legality, cost, and access vary widely by jurisdiction. Some places have medical cannabis programs that explicitly include cancer patients; others do not. Discuss options with your medical team.
Key takeaway: If you are considering cannabis during cancer treatment, tell your oncologist. Not to ask permission, but because they need to know for safe prescribing, interaction management, and treatment monitoring.
Medical disclaimer
This article is not medical advice. It summarizes published scientific evidence as of October 2026. It is not a substitute for consultation with a qualified oncology team.
Do not stop, delay, reduce, or replace cancer treatment based on anything you read here or anywhere else on the internet. Cannabis and cannabinoid medicines have real uses in supportive oncology care—managing nausea, pain, appetite, and sleep—but they work best as part of a comprehensive plan your medical team knows about and has approved.
Cancer treatment decisions are complex and individual. Your oncologist, nurses, and pharmacist know your diagnosis, stage, treatments, medications, and medical history. They are your best resource for whether cannabis is appropriate and safe for you.
Sources
- Peer-reviewed Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database of Systematic Reviews. 2015;11:CD009464.
- Government National Cancer Institute (US). Cannabis and Cannabinoids (PDQ®) – Health Professional Version. Updated 2024.
- Peer-reviewed Pergam SA, Woodfield MC, Lee CM, et al. Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. Cancer. 2017;123(22):4488–4497.
- Peer-reviewed Velasco G, Sánchez C, Guzmán M. Anticancer mechanisms of cannabinoids. Current Oncology. 2016;23(Suppl 2):S23–S32.
- Peer-reviewed Abrams DI. The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report. European Journal of Internal Medicine. 2018;49:7–11.
- Peer-reviewed Johnson SB, Park HS, Gross CP, Yu JB. Use of Alternative Medicine for Cancer and Its Impact on Survival. Journal of the National Cancer Institute. 2018;110(1):121–124.
- Peer-reviewed Ruiz-García V, López-Briz E, Carbonell-Sanchis R, et al. Megestrol acetate for cachexia-anorexia syndrome. A systematic review. Journal of Cachexia, Sarcopenia and Muscle. 2018;9(3):444–452.
- Peer-reviewed Brown JD, Winterstein AG. Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. Journal of Clinical Medicine. 2019;8(7):989.
- Peer-reviewed Fallon MT, Albert Lux E, McQuade R, et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain. 2017;11(3):119–133.
- Peer-reviewed Strasser F, Luftner D, Possinger K, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome. Journal of Clinical Oncology. 2006;24(21):3394–3400.
- Peer-reviewed Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. British Journal of Cancer. 2006;95(2):197–203.
- Peer-reviewed Twelves C, Sabel M, Checketts D, et al. A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma. British Journal of Cancer. 2021;124:1379–1387.
- Peer-reviewed Taha T, Meiri D, Talhamy S, Wollner M, Peer A, Bar-Sela G. Cannabis impacts tumor response rate to nivolumab in patients with advanced malignancies. The Oncologist. 2019;24(4):549–554.
- Peer-reviewed Ruchlemer R, Amit-Kohn M, Raveh D, Hanuš L. Inhaled medicinal cannabis and the immunocompromised patient. Supportive Care in Cancer. 2015;23(3):819–822.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis and Cancer Cachexia — Cannabis improves appetite reports, but has weak evidence for reversing muscle wasting.
- Cannabis and Cancer — Evidence-based overview of cannabis in cancer supportive care, symptom management, and doc...
- Cannabis and Cancer Pain — Evidence-based overview of cannabis medicines for cancer pain management.
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.